Ildikó Kocsmár

Ildikó Kocsmár

Auto-generated profile, based on publicly available information

Ildikó Kocsmár

Department of Pathology, Forensic and Insurance Medicine, Semmelweis University, Budapest, Hungary

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 April 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
ÉKÉva Kocsmár
Éva Kocsmár
GBGyörgy Miklós Buzás
György Miklós Buzás
ISIldikó Szirtes
Ildikó Szirtes
IKIldikó Kocsmár
Ildikó Kocsmár
ZKZsófia Kramer
Zsófia Kramer
GLGábor Lotz
Gábor Lotz
Clarithromycin is a macrolide antibiotic widely used for eradication ofHelicobacter pyloriinfection, and thus resistance to this antibiotic is a major cause of treatment failure. Here, we present the results of a retrospective observational study of clarithromycin resistance (Cla-res) in 4744H. pylori-infected patients from Central Hungary. We use immunohistochemistry and fluorescence in situ hybridization on fixed gastric tissue samples to determineH. pyloriinfection and to infer Cla-res status, respectively. We correlate this information with macrolide dispensing data for the same patients (available through a prescription database) and develop a mathematical model of the population dynamics of Cla-resH. pyloriinfections. Cla-res is found in 5.5% of macrolide-naive patients (primary Cla-res), with no significant sex difference. The model predicts that this primary Cla-res originates from transmission of resistant bacteria in 98.7% of cases, and derives from spontaneous mutations in the other 1.3%. We find an age-dependent preponderance of female patients among secondary (macrolide-exposed) clarithromycin-resistant infections, predominantly associated with prior use of macrolides for non-eradication purposes. Our results shed light into the sources of primary resistant cases, and indicate that the growth rate of Cla-res prevalence would likely decrease if macrolides were no longer used for purposes other thanH. pylorieradication.

5 April 2023 in Cellular and Molecular Life Sciences
Verified
Journal Article
Open access
PDF file
ÉKÉva Kocsmár
Éva Kocsmár
MSMarlene Schmid
Marlene Schmid
MCMiguel Cosenza-Contreras
Miguel Cosenza-Contreras
IKIldikó Kocsmár
Ildikó Kocsmár
MFMelanie Foell
Melanie Foell
PBPeter Bronsert
Peter Bronsert
Protein expression is a primary area of interest for routine histological diagnostics and tissue-based research projects, but the limitations of its post-mortem applicability remain largely unclear. On the other hand, tissue specimens obtained during autopsies can provide unique insight into advanced disease states, especially in cancer research. Therefore, we aimed to identify the maximum post-mortem interval (PMI) which is still suitable for characterizing protein expression patterns, to explore organ-specific differences in protein degradation, and to investigate whether certain proteins follow specific degradation kinetics. Therefore, the proteome of human tissue samples obtained during routine autopsies of deceased patients with accurate PMI (6, 12, 18, 24, 48, 72, 96 h) and without specific diseases that significantly affect tissue preservation, from lungs, kidneys and livers, was analyzed by liquid chromatography–tandem mass spectrometry (LC–MS/MS). For the kidney and liver, significant protein degradation became apparent at 48 h. For the lung, the proteome composition was rather static for up to 48 h and substantial protein degradation was detected only at 72 h suggesting that degradation kinetics appear to be organ specific. More detailed analyses suggested that proteins with similar post-mortem kinetics are not primarily shared in their biological functions. The overrepresentation of protein families with analogous structural motifs in the kidney indicates that structural features may be a common factor in determining similar postmortem stability. Our study demonstrates that a longer post-mortem period may have a significant impact on proteome composition, but sampling within 24 h may be appropriate, as degradation is within acceptable limits even in organs with faster autolysis.

17 December 2020 in Scientific Reports
Verified
Journal Article
Open access
PDF file
ÉKÉva Kocsmár
Éva Kocsmár
IKIldikó Kocsmár
Ildikó Kocsmár
LSLuca Szalai
Luca Szalai
GLGábor Lendvai
Gábor Lendvai
ASAttila Szijártó
Attila Szijártó
GLGábor Lotz
Gábor Lotz
Small subtype of the gastrointestinal stromal tumor (micro-GIST, MG) is usually asymptomatic and is frequently found incidentally in association with gastric adenocarcinoma (GAC). The background of this coincidence is still an open question. This study comprehensively characterized nine MGs and GACs present in the same surgical specimen by cross-testing the markers of the major pathogenetic pathways of both tumor types. All of the MGs were immunohistochemically positive for CD117/KIT, CD34, and DOG1. DOG1 was also detected in four GACs. Four MGs carried mutations in c-KIT (exons 9, 11, and 13) and two cases in PDGFRα (exon 18). None of the GACs carried activating mutations in c-KIT or PDGFRα. MMR immunopanel identified one GAC as microsatellite unstable tumor. No EBV-positive tumor was found. According to the TCGA molecular classification, one GAC was categorized in the MSI subgroup, three GACs in the genomically stable subgroup, and the rest into the chromosomal instability subgroup. Although a common carcinogenic effect cannot be ruled out, our data suggest a distinct molecular background in the evolvement of the synchronous MGs and GACs. The presence of a MG in gastric resection specimens may be indicative of the development of synchronous malignant tumors in or outside the stomach.

30 April 2024 in GeroScience
Verified
Journal Article
Open access
PDF file
ÉKÉva Kocsmár
Éva Kocsmár
IKIldikó Kocsmár
Ildikó Kocsmár
FEFlóra Elamin
Flóra Elamin
LPLaura Pápai
Laura Pápai
ÁJÁkos Jakab
Ákos Jakab
GLGábor Lotz
Gábor Lotz
COVID-19, caused by SARS-CoV-2, manifests with differing severity across distinct patient subgroups, with outcomes influenced by underlying comorbidities such as cancer, which may cause functional and compositional alterations of the immune system during tumor progression. We aimed to investigate the association of SARS-CoV-2 infection and its complications with cancer in a large autopsy series and the role of COVID-19 in the fatal sequence leading to death. A total of 2641 adult autopsies were investigated, 539 of these were positive for SARS-CoV-2. Among the total number of patients analyzed, 829 had active cancer. Overall, the cohort included 100 patients who simultaneously had cancer and SARS-CoV-2 infection. The course of COVID-19 was less severe in cancer patients, including a significantly lower incidence of viral and bacterial pneumonia, occurring more frequently as a contributory disease or coexisting morbidity, or as SARS-CoV-2 positivity without viral disease. SARS-CoV-2 positivity was more frequent among non-metastatic than metastatic cancer cases, and in specific tumor types including hematologic malignancies. COVID-19 was more frequently found to be directly involved in the fatal sequence in patients undergoing active anticancer therapy, but less frequently in perioperative status, suggesting that the underlying malignancy and consequent surgery are more important factors leading to death perioperatively than viral disease. The course of COVID-19 in cancer patients was milder and balanced during the pandemic. This may be due to relative immunosuppressed status, and the fact that even early/mild viral infections can easily upset their condition, leading to death from their underlying cancer or its complications.


25 September 2026 in Histopathology
Verified
Journal Article
Open access
PDF file
ÁJÁkos Jakab
Ákos Jakab
LSLuca Szalai
Luca Szalai
BZBettina Zengő
Bettina Zengő
IKIldikó Kocsmár
Ildikó Kocsmár
TVTibor Várkonyi
Tibor Várkonyi
ÉKÉva Kocsmár
Éva Kocsmár
Background: The Stroma AReactive Invasion Front Areas (SARIFA) is a novel histological phenomenon characterized by direct tumour cell‐adipocyte interaction without intervening stroma or inflammatory cells and easily identifiable in routine haematoxylin–eosin‐stained sections. Methods: This study evaluated the prognostic significance of SARIFA in a cohort consisting of 333 gastric cancer patients, including 171 intestinal and 162 non‐intestinal adenocarcinoma cases. Associations between SARIFA and various well‐known histopathological tumour parameters, including lymphovascular invasion, perineural invasion, tumour budding and poorly differentiated clusters (PDCs), were investigated and the prognostic value of these features for survival was determined. Results: SARIFA was more frequently observed in non‐intestinal carcinomas but was significantly associated with lymphovascular and perineural invasion in both gastric cancer subtypes. Number of SARIFA foci showed a weak positive correlation with the number of tumour buds and PDCs. SARIFA was identified as an independent negative prognostic factor for overall survival in non‐intestinal gastric cancers. According to time‐dependent ROC curve analysis, quantification of SARIFA foci did not increase the prognostic accuracy beyond detecting their absence or presence in both gastric cancer subtypes. In addition, the lymph node ratio in both subcohorts and perineural invasion in intestinal adenocarcinomas were also found to be independent prognostic factors for overall survival. Conclusion: SARIFA is a robust, easily assessable histological marker with independent prognostic value in non‐intestinal gastric adenocarcinomas. Reliable histopathological markers for this group of tumours, characterized by their distinctive morphology and infiltration pattern, remain limited. Integration of SARIFA into routine diagnostics may enhance risk stratification.